Compounds > lauroylcarnitine
Page last updated: 2024-11-08

lauroylcarnitine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lauroylcarnitine: RN refers to hydroxide inner salt, (R)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

O-lauroyl-L-carnitine : An O-acyl-L-carnitine in which the acyl group is specified as lauroyl (dodecanoyl). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID168381
CHEBI ID77086
SCHEMBL ID1958560
MeSH IDM0242822

Synonyms (39)

Synonym
lauroyl-l(-)-carnitin [german]
(-)-lauroylcarnitine
l-carnitine dodecanoyl ester
ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, laurate, l-
dodecanoyl-l-carnitine
lauroylcarnitine
lauroyl-l-carnitine
1-propanaminium, 3-carboxy-n,n,n-trimethyl-2-((1-oxododecyl)oxy)-, inner salt, (r)-
(r)-dodecanoylcarnitine
c12 carnitine
dodecanoylcarnitine
25518-54-1
(3r)-3-dodecanoyloxy-4-(trimethylazaniumyl)butanoate
w05iwq0v44 ,
unii-w05iwq0v44
lauroyl-l(-)-carnitin
o-lauroyl-l-carnitine
(3r)-3-(dodecanoyloxy)-4-(trimethylammonio)butanoate
(3r)-3-(dodecanoyloxy)-4-(trimethylazaniumyl)butanoate
CHEBI:77086
o-dodecanoyl-r-carnitine
SCHEMBL1958560
FUJLYHJROOYKRA-QGZVFWFLSA-N
l-lauroylcarnitine
lauroyllevocarnitine
1-propanaminium, 3-carboxy-n,n,n-trimethyl-2-((1-oxododecyl)oxy)-, inner salt, (2r)-
lauroyl-l(-)-carnitine
LMFA07070062
o-dodecanoyl-l-carnitine
lauroyl-l-carnitine, >=97.0% (tlc)
AS-68308
c12 carnitine, lauroyl l-carnitine, powder
Q27146632
HY-113166
CS-0062327
(r)-3-(dodecanoyloxy)-4-(trimethylammonio)butanoate
AKOS037646352
(3r)-3-dodecanoyloxy-4-trimethylammonio-butanoate
DTXSID001036034

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Plasma calcium level was measured and pharmacological bioavailability (P."( Enhancement of nasal salmon calcitonin absorption by lauroylcarnitine chloride in rats.
Fukui, M; Hasumi, S; Kagatani, S; Ohmura, T; Shinoda, T; Sonobe, T, 1996)		0.54
"This study was undertaken to investigate the bioavailability of various L-carnitine esters (acetyl-L-carnitine and lauroyl-L-carnitine) and salts (L-carnitine L-tartrate, L-carnitine fumarate, L-carnitine magnesium citrate) relative to base of free L-carnitine."( Free and total carnitine concentrations in pig plasma after oral ingestion of various L-carnitine compounds.
Becker, K; Eder, K; Felgner, J; Kluge, H, 2005)		0.33
"We examined the effect of acylcarnitines on the in situ bioavailability of lucifer yellow (LY) from the loops of small and large intestines of rats."( Increases in bioavailability of poorly absorbed drug by acylcarnitine.
Doi, N; Hayashi, M; Kimura, A; Tomita, M, 2012)		0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
O-dodecanoylcarnitineAn O-acylcarnitine having dodecanoyl as the acyl substituent.
dodecanoate esterAny fatty acid ester in which the carboxylic acid component is lauric acid.
saturated fatty acyl-L-carnitineAn O-acylcarnitine in which the R is a saturated fatty acyl chain.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (18.18)18.2507
2000's2 (18.18)29.6817
2010's7 (63.64)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.99 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetylcarnitine
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.		2.9410O-acylcarnitinehuman metabolite
carnitine
[no description available]		9.75110amino-acid betainehuman metabolite;
mouse metabolite
fluorescein-5-isothiocyanate
Fluorescein-5-isothiocyanate: Fluorescent probe capable of being conjugated to tissue and proteins. It is used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.. fluorescein 5-isothiocyanate : The 5-isomer of fluorescein isothiocyanate. Acts as a fluorescent probe capable of being conjugated to tissue and proteins; used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.		2.4620fluorescein isothiocyanate
s-adenosylmethionine
acylcarnitine: structure in first source. S-adenosyl-L-methioninate : A sulfonium betaine that is a conjugate base of S-adenosyl-L-methionine obtained by the deprotonation of the carboxy group.		3.0240sulfonium betainehuman metabolite
tartaric acid
tartaric acid: RN given refers to cpd with unspecified isomeric designation. D-tartaric acid : The D-enantiomer of tartaric acid.		2.9410tartaric acidEscherichia coli metabolite
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		2.0610cyclodextrin
polidocanol
Polidocanol: An alkyl polyglycol ether of LAURYL ALCOHOL, chemically defined as an alcohol ethoxylate having an average alkyl chain of 12–14 carbon atoms, and an ethylene oxide chain of 9 ethylene oxide units. It is used as a detergent, and medically as a local anesthetic, and as a sclerosing agent for the treatment of ESOPHAGEAL AND GASTRIC VARICES and VARICOSE VEINS.. polidocanol : A hydroxypolyether that is nonaethylene glycol in which one of the terminal hydroxy functions is substituted by a lauryl (dodecyl) group.		2.1510hydroxypolyetherhepatotoxic agent;
nonionic surfactant;
sclerotherapy agent
sphingosine
sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.		1.9810sphing-4-eninehuman metabolite;
mouse metabolite
lysophosphatidylcholines
lysophosphatidylcholine : An acylglycerophosphocholine resulting from partial hydrolysis of a phosphatidylcholine, which removes one of the fatty acyl groups. The structure is depicted in the image where R1 = acyl, R2 = H or where R1 = H, R2 = acyl.		1.98101-O-acyl-sn-glycero-3-phosphocholine
hexanoylcarnitine
hexanoylcarnitine: RN given refers to chloride salt; RN for parent cpd not available 11/89. O-hexanoylcarnitine : An O-acylcarnitine compound having hexanoyl as the acyl substituent.		2.110hexanoate ester;
O-acylcarnitine		human metabolite
carbobenzoxyglycylphenylalanine
carbobenzoxyglycylphenylalanine: used as substrate for carboxypeptidase B; RN given refers to (L-Phe)-isomer		1.9810
octanoylcarnitine
octanoylcarnitine: RN given refers to cpd without isomeric designation. O-octanoyl-L-carnitine : The L-enantiomer of an O-octanoylcarnitine.		2.110O-octanoylcarnitine;
saturated fatty acyl-L-carnitine		human metabolite
palmitoylcarnitine
Palmitoylcarnitine: A long-chain fatty acid ester of carnitine which facilitates the transfer of long-chain fatty acids from cytoplasm into mitochondria during the oxidation of fatty acids.. O-palmitoyl-L-carnitine : An O-acyl-L-carnitine in which the acyl group is specified as palmitoyl (hexadecanoyl).		2.9540O-palmitoylcarnitine;
saturated fatty acyl-L-carnitine		EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
human metabolite;
mouse metabolite
calcitonin
[no description available]		6.9910
lucifer yellow
lucifer yellow: RN given refers to di-Li salt		2.4720organic lithium saltfluorochrome
vasoactive intestinal peptide
Vasoactive Intestinal Peptide: A highly basic, 28 amino acid neuropeptide released from intestinal mucosa. It has a wide range of biological actions affecting the cardiovascular, gastrointestinal, and respiratory systems and is neuroprotective. It binds special receptors (RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE).		2.0110
ConditionIndicatedRelationship StrengthStudiesTrials
Cardiometabolic Syndrome
A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.		02.0710
Innate Inflammatory Response
[description not available]		02.0710
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0710
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		02.0710
Metabolic Syndrome
A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.		02.0710